Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Chul Kim, MD, MPH
Advertisement
Articles by Chul Kim, MD, MPH
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5